These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 25951504)
21. Pharmacoeconomic study of chronic constipation in a secondary care centre. Walsh C; Murphy J; Quigley EM Ir J Med Sci; 2015 Dec; 184(4):863-70. PubMed ID: 25287934 [TBL] [Abstract][Full Text] [Related]
22. [Evaluation of the efficacy of prucalopride (resolor) in the treatment of patients with chronic constipation]. Osipenko MF; Bikbulatova EA; Skalinskaia MA; Kulygina IuA; Pankova LIu Ter Arkh; 2013; 85(12):60-4. PubMed ID: 24640670 [TBL] [Abstract][Full Text] [Related]
23. Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation. Tack J; Corsetti M Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1327-35. PubMed ID: 22985444 [TBL] [Abstract][Full Text] [Related]
24. Oral prucalopride in children with functional constipation. Winter HS; Di Lorenzo C; Benninga MA; Gilger MA; Kearns GL; Hyman PE; Vandeplassche L; Ausma J; Hoppenbrouwers M J Pediatr Gastroenterol Nutr; 2013 Aug; 57(2):197-203. PubMed ID: 23535761 [TBL] [Abstract][Full Text] [Related]
26. A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation. Yiannakou Y; Piessevaux H; Bouchoucha M; Schiefke I; Filip R; Gabalec L; Dina I; Stephenson D; Kerstens R; Etherson K; Levine A Am J Gastroenterol; 2015 May; 110(5):741-8. PubMed ID: 25869393 [TBL] [Abstract][Full Text] [Related]
27. Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation. Dubois D; Gilet H; Viala-Danten M; Tack J Neurogastroenterol Motil; 2010 Feb; 22(2):e54-63. PubMed ID: 19761492 [TBL] [Abstract][Full Text] [Related]
28. Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. Vigone B; Caronni M; Severino A; Bellocchi C; Baldassarri AR; Fraquelli M; Montanelli G; Santaniello A; Beretta L Arthritis Res Ther; 2017 Jun; 19(1):145. PubMed ID: 28633671 [TBL] [Abstract][Full Text] [Related]
29. Prucalopride induces high-amplitude propagating contractions in the colon of patients with chronic constipation: a randomized study. Miner PB; Camilleri M; Burton D; Achenbach H; Wan H; Dragone J; Mellgard B Neurogastroenterol Motil; 2016 Sep; 28(9):1341-8. PubMed ID: 27270968 [TBL] [Abstract][Full Text] [Related]
30. An overview of the efficacy and safety of prucalopride for the treatment of chronic idiopathic constipation. Daniali M; Nikfar S; Abdollahi M Expert Opin Pharmacother; 2019 Dec; 20(17):2073-2080. PubMed ID: 31557072 [No Abstract] [Full Text] [Related]
31. Use of prucalopride in adults with chronic idiopathic constipation. Vijayvargiya P; Camilleri M Expert Rev Clin Pharmacol; 2019 Jul; 12(7):579-589. PubMed ID: 31096799 [No Abstract] [Full Text] [Related]
32. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Krogh K; Jensen MB; Gandrup P; Laurberg S; Nilsson J; Kerstens R; De Pauw M Scand J Gastroenterol; 2002 Apr; 37(4):431-6. PubMed ID: 11989834 [TBL] [Abstract][Full Text] [Related]
34. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Emmanuel AV; Roy AJ; Nicholls TJ; Kamm MA Aliment Pharmacol Ther; 2002 Jul; 16(7):1347-56. PubMed ID: 12144586 [TBL] [Abstract][Full Text] [Related]
35. Prucalopride improves bowel function and colonic transit time in patients with chronic constipation: an integrated analysis. Emmanuel A; Cools M; Vandeplassche L; Kerstens R Am J Gastroenterol; 2014 Jun; 109(6):887-94. PubMed ID: 24732867 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety analysis of prucalopride in refractory chronic constipation cases in a tertiary care hospital in Eastern India: A randomized, single-blind, placebo-controlled study. Dehury S; Mohapatra S; Das HS; Goutam S; Kaushik C Indian J Pharmacol; 2023; 55(1):6-13. PubMed ID: 36960515 [TBL] [Abstract][Full Text] [Related]
37. Prucalopride for the treatment of constipation: a view from 2015 and beyond. Bassotti G; Usai Satta P; Bellini M Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):257-262. PubMed ID: 30791758 [TBL] [Abstract][Full Text] [Related]
38. Prucalopride is no more effective than placebo for children with functional constipation. Mugie SM; Korczowski B; Bodi P; Green A; Kerstens R; Ausma J; Ruth M; Levine A; Benninga MA Gastroenterology; 2014 Dec; 147(6):1285-95.e1. PubMed ID: 25239590 [TBL] [Abstract][Full Text] [Related]
39. A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States. Cash BD; Lu M; Lembo A; Feuerstadt P; Nguyen L; Terasawa E; Ayyagari R; Du S; Pi S; Westermeyer B; Terreri B; Boules M; Moshiree B J Manag Care Spec Pharm; 2024 Oct; 30(10):1136-1148. PubMed ID: 39321115 [TBL] [Abstract][Full Text] [Related]
40. Prucalopride: a review of its use in the management of chronic constipation. Keating GM Drugs; 2013 Nov; 73(17):1935-50. PubMed ID: 24194435 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]